Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
10.53
+0.01 (0.10%)
At close: Aug 5, 2026, 4:00 PM EDT
10.39
-0.14 (-1.33%)
After-hours: Aug 5, 2026, 7:50 PM EDT
Zevra Therapeutics Employees
Zevra Therapeutics had 61 employees as of December 31, 2025. The number of employees increased by 2 or 3.39% compared to the previous year.
Employees
61
Change (1Y)
2
Growth (1Y)
3.39%
Revenue / Employee
$2,230,672
Profits / Employee
$862,607
Market Cap
622.48M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 61 | 2 | 3.39% | 61 | 0 |
| Dec 31, 2024 | 59 | -10 | -14.49% | 59 | 0 |
| Dec 31, 2023 | 69 | 33 | 91.67% | 65 | 4 |
| Dec 31, 2022 | 36 | 12 | 50.00% | 32 | 4 |
| Dec 31, 2021 | 24 | 2 | 9.09% | 24 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Ginkgo Bioworks Holdings | 485 |
| REGENXBIO | 371 |
| Phathom Pharmaceuticals | 371 |
| CorMedix | 191 |
| Allogene Therapeutics | 152 |
| MapLight Therapeutics | 133 |
| Cybin | 100 |
ZVRA News
- 5 hours ago - Zevra Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 5 hours ago - Zevra Therapeutics Earnings release: Q2 2026 - Filings
- 5 hours ago - Zevra Therapeutics Quarterly report: Q2 2026 - Filings
- 5 hours ago - Zevra Reports Second Quarter 2026 Financial Results and Corporate Update - GlobeNewsWire
- 5 hours ago - Zevra Therapeutics Slides: Corporate presentation - Filings
- 1 day ago - Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference - GlobeNewsWire
- 2 days ago - Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC) - GlobeNewsWire
- 9 days ago - ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law - Business Wire